Cyclin-Dependent Kinase Inhibitor p18
"Cyclin-Dependent Kinase Inhibitor p18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An INK4 cyclin-dependent kinase inhibitor containing five ANKYRIN-LIKE REPEATS. Aberrant expression of this protein has been associated with deregulated EPITHELIAL CELL growth, organ enlargement, and a variety of NEOPLASMS.
| Descriptor ID |
D050763
|
| MeSH Number(s) |
D12.644.360.225.300 D12.776.167.187.300 D12.776.476.225.300 D12.776.624.776.355.300
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p18- Cyclin-Dependent Kinase Inhibitor p18
- Cyclin Dependent Kinase Inhibitor p18
- p18 CDK6 Inhibitor
- CDK6 Inhibitor, p18
- CDK6-Associated Protein p18
- CDK6 Associated Protein p18
- p18, CDK6-Associated Protein
- p18INK4c Protein
- Cyclin-Dependent Kinase Inhibitor 2C
- Cyclin Dependent Kinase Inhibitor 2C
- INK4C Protein
- CDKN2C Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p18".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p18".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p18" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 2 | 0 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 4 | 1 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p18" by people in Profiles.
-
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
-
Absence of cyclin-dependent kinase inhibitor p27 or p18 increases efficiency of iPSC generation without induction of iPSC genomic instability. Cell Death Dis. 2019 03 20; 10(4):271.
-
Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer. 2018 Jul 24; 18(1):758.
-
CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797.
-
Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer. 2018 Jan 01; 124(1):84-94.
-
Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma. Ann Clin Lab Sci. 2017 Sep; 47(5):523-528.
-
Performance of in silico tools for the evaluation of p16INK4a (CDKN2A) variants in CAGI. Hum Mutat. 2017 09; 38(9):1042-1050.
-
Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 04; 16(4):662-670.
-
Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016 11; 26(11):1553-1562.
-
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 07 01; 7:12050.